Search the Newsreel

Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest Reading - Low Growth Earnings

Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest Reading - Guidance Accuracy Score

Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary

Pasithea Therapeutics Corp. reported a Q2 2026 net loss of $(5.27M) and diluted EPS of $(0.16), marking a wider loss compared to the previous year. The company is advancing its PAS-004 clinical development programs, with a significant increase in R&D expenses. Pasithea has refocused …

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock

Vivo Opportunity entities, including Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., have reported beneficial ownership of 9.99% of Pasithea Therapeutics (KTTA) common stock. These holdings comprise a mix of common shares and pre-funded warrants, which include provisions to prevent ownership …

KTTA Q1 2026 Earnings: Narrower-than-Expected Loss of $0.12 Per Share Highlights Cost Control - Debt Analysis Report

Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW

This article provides financial information for Pasithea Therapeutics Corp. (NASDAQ: KTTAW), specifically focusing on its enterprise value to EBIT forward. It indicates that the company's financial data is provided by ICE Data Services and FactSet Research Systems Inc. The article is hosted on TradingView, …

Pasithea Therapeutics (KTTA) Jumps 14% as Price Approaches Key Resistance - Fibonacci Time Zone

Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026)

This article reports on an SEC filing (Form ARS) by Pasithea Therapeutics Corp. (KTTA) on August 7, 2026. The filing has a low impact and neutral sentiment according to AI analysis. The article also provides recent news and other SEC filings for KTTA, along …

Enterprise value to EBITDA forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW

This article displays the "Enterprise value to EBITDA forward" metric for Pasithea Therapeutics Corp. (NASDAQ:KTTAW). The content primarily consists of navigation and branding elements from TradingView, indicating that the core data is presented within a graphical or tabular format on their platform, which is …

Price to sales forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW

The article focuses on the "Price to sales forward" financial metric for Pasithea Therapeutics Corp. (NASDAQ: KTTAW), accessible through TradingView. It appears to be a financial data page, indicating that this specific data point is currently unavailable or not displayed.

Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A

Opaleye Management Inc., Opaleye, L.P., and James Silverman have collectively reported a beneficial ownership of 2,050,000 shares of Pasithea Therapeutics Corp. (NASDAQ: KTTA) common stock, representing 6.14% of the outstanding class. This disclosure was made in an amended Schedule 13G/A filing, indicating shared voting …

Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote

Pasithea Therapeutics (NASDAQ: KTTA) is holding a virtual annual stockholder meeting on September 9, 2026, where key votes include the election of two Class III directors, ratification of CBIZ as the independent accounting firm for 2026, and approval of a reverse stock split. The …

Pasithea Therapeutics Corp (KTTA) Cash Flow

This article provides a detailed cash flow statement for Pasithea Therapeutics Corp (KTTA), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow metrics like operating, investing, financing, and free cash flow, explaining their significance for investors. …

Pasithea Therapeutics Corp (KTTA) Institutional Confidence

This article from TradingKey provides an overview of institutional holdings in Pasithea Therapeutics Corp (KTTA). It lists several investment firms, including Squadron Capital Management LLC and Vivo Capital, LLC, and their respective shareholdings in the company. The report highlights the "Institutional Confidence" section as …

Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pasithea Therapeutics Corp (KTTA) stock information, including its market capitalization, current trading price, and historical data on dividends and stock splits. It indicates that the company has not distributed any dividends in the past five years but underwent …

Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The TradingKey article on Pasithea Therapeutics Corp (KTTA) states that relevant financial data regarding the company's revenue breakdown by business segments and regions has not been disclosed by the company yet. It provides current stock information including a market cap of $15.20M and a …

Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pasithea Therapeutics Corp (KTTA), identifying major institutional holders like Opaleye Management Inc., Squadron Capital Management LLC, and Vivo Capital, LLC. It also breaks down shareholder types, including hedge funds and investment advisors, and provides a history of …

Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Pasithea Therapeutics Corp (KTTA), focusing on its P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these metrics have not yet been disclosed by the company. The article presents the current stock price, market …

KTTA|Pasithea Therapeutics Corp|Price:0.455|Chg%:-0.025

This article provides an overview of Pasithea Therapeutics Corp (KTTA) stock performance, showing a price of $0.455 with a 5.25% decrease. It details how TradingKey generates its stock scores across various dimensions like financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk …

Pasithea Therapeutics (KTTA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise Amid Revenue Absence - Annual Report

KTTA Q1 2026 Earnings: EPS Surprises to the Upside Despite No Revenue - Earnings Season Review

KTTA Q1 2026 Earnings: Significant EPS Beat Despite No Revenue; Stock Gains 4.4% - New Analyst Coverage

KTTA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Investor Sentiment - Low Estimate Range

Pasithea Therapeutics (KTTA) Registration filing Summary

Pasithea Therapeutics (KTTA) is a clinical-stage biotechnology company focused on treatments for CNS disorders, RASopathies, MAPK pathway-driven tumors, and other diseases. The company reported net losses of $13.9 million in 2024 and $16.0 million in 2023, with an accumulated deficit of $59.9 million as …

Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors

Pasithea Therapeutics Corp. announced that its Phase 1 dose-escalation study for PAS-004, a macrocyclic MEK inhibitor, has been accepted for a poster presentation at the ESMO Congress 2026 on October 23. The study focuses on the safety and pharmacokinetics of PAS-004 in patients with …

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

Pasithea Therapeutics announced that data from its Phase 1 dose-escalation study of PAS-004, a macrocyclic MEK inhibitor, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation will detail the safety and pharmacokinetics of PAS-004 for treating MAPK pathway-driven …